A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 01 Feb 2019
At a glance
- Drugs Ribociclib (Primary) ; Letrozole
- Indications Breast cancer
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 23 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated
- 19 Jun 2018 Planned End Date changed from 16 Dec 2019 to 14 May 2021.